Ubrogepant
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Ubrogepant is used to treat migraine disorders, migraine with aura and migraine without aura, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 23, 2019. In 2024, Medicare Part D spent $430 million on Ubrogepant across 328,000 claims for 83,000 beneficiaries.
Ubrogepant is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $108.91 to $109.14 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$108.91 – $109.14
per EA
7d Activity
avg -0.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing UBROGEPANT
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
UBRELVY 100 MG TABLET | $109.1352 per EA | -0.04% |
UBRELVY 100 MG TABLET | $109.1352 per EA | -0.04% |
UBRELVY 50 MG TABLET | $108.9099 per EA | -0.01% |
Frequently Asked Questions
What is Ubrogepant used to treat?
Ubrogepant is used to treat migraine disorders, migraine with aura and migraine without aura, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Ubrogepant?
In 2024, Medicare Part D spent $430 million on Ubrogepant across 328,000 claims for 83,000 beneficiaries.
How many Ubrogepant products are on the market?
The Ubrogepant drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Ubrogepant?
NADAC reference prices for Ubrogepant range from $108.9099 to $109.1352 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Ubrogepant?
1 manufacturer lists Ubrogepant in NADAC. Ranked by number of NDCs, the largest are Allergan, Inc. (3).
How has the price of Ubrogepant changed recently?
Over the past 7 days, 0 Ubrogepant NDCs rose and 3 fell, with a market-wide average change of -0.0%.